Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference
August 28 2019 - 7:00AM
Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical
dermatology company committed to the development and
commercialization of novel treatments that provide meaningful
benefit for people living with skin diseases, today announced that
Ted White, Verrica President and CEO, will present a business
overview and review of the company’s pipeline programs at the H.C.
Wainwright 21st Annual Global Investment Conference in New York, NY
on Monday, September 9, 2019 at 3:00 p.m. ET.
A live audio webcast of the event will be available
in the Investors/Events & Presentations section of the Verrica
website at http://www.verrica.com. A webcast replay will also be
available on this website shortly after conclusion of the event for
30 days.
About Verrica Pharmaceuticals Inc.
Verrica is a medical dermatology company committed
to the development and commercialization of novel treatments that
provide meaningful benefit for people living with skin diseases.
The company’s late-stage product candidate, VP-102, is a potential
first-in-class topical therapy for the treatment of molluscum
contagiosum and common warts. Molluscum is a highly contagious
viral skin infection affecting approximately six million people,
primarily children, in the United States, and common warts are
contagious skin growths affecting 22 million people. There are
currently no FDA-approved treatments for molluscum or common warts.
Following positive topline results from two pivotal Phase 3 trials,
a New Drug Application for VP-102 for the treatment of molluscum is
planned for the second half of 2019. Verrica is planning to meet
with the FDA to determine next steps on the development of VP-102
for common warts following positive Phase 2 results. VP-102 is also
currently in a Phase 2 trial for the treatment of external genital
warts. A second product candidate, VP-103, is in pre-clinical
development for plantar warts. For more information, visit
www.verrica.com.
Contacts
Investors:
Chris DegnanChief Financial
Officer484.453.3300 ext. 103info@verrica.com
Chiara RussoSolebury
Trout617.221.9197crusso@soleburytrout.com
Media:
Joshua R. MansbachSolebury
Trout646-378-2964jmansbach@troutgroup.com
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Verrica Parmaceuticals (NASDAQ:VRCA)
Historical Stock Chart
From Apr 2023 to Apr 2024